A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors

Jayesh Desai, Ben Markman, Shahneen Kaur Sandhu, Hui Kong Gan, Michael Friedlander, Ben Tran, Tarek Meniawy, Vishal Boolell, Duncan Colyer, Christie Norris, Malaka Ameratunga, Jason Yang, Kang Li, Lai Wang, Lusong Luo, Zhen Qin, Michael Millward

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

2 Citations (Web of Science)
Original languageEnglish
Number of pages2
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2016
Event52nd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States
Duration: 3 Jun 20167 Jun 2016

Cite this